Similar Items: Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema
- Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
- Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials
- Letter to the Editor Regarding “Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials”
- A Response to: Letter to the Editor Regarding “Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials”
- Visual Gains with Faricimab vs Aflibercept 8 mg in Naïve Retinovascular Disease: Global Real-World Cases and Literature Review
- Advances in Polypoidal Choroidal Vasculopathy (PCV) Management: Emerging Evidence for Faricimab and Aflibercept 8 mg